| Patient | Alan Turing |
|---|---|
| Date of birth | 1912-06-23 |
| Identifiers | MRN HR-ML007-SYN-TD; SSN (made up) 000-07-6290 |
| Document date | 1953-04-28 |
| Author | Rupert Hallam, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week follow-up; endocrinology consultation and scrotal ultrasound today. [S]
Mr. Turing returns two weeks after his first visit, five weeks after the last estrogen injection. He saw Dr. Montrose-Adeyemi of endocrinology this morning and had a scrotal ultrasound, which was normal. His breasts are still tender against his shirt, with no change in size, and he has had no nipple discharge. Libido and morning erections are still absent. He has had two sessions with the clinic psychologist and found them easier than he expected; they have begun with what was done to him rather than with his sexuality, which he says he has never regarded as the problem. He sleeps five to six hours and has run twice this week, alone. He has had no suicidal thoughts and keeps his safety plan on his phone. He takes cholecalciferol daily. [S]
| Element | Detail |
|---|---|
| Breasts | Still tender; no change in size; no discharge |
| Sexual function | Libido and morning erections still absent |
| Psychotherapy | Two sessions with the clinic psychologist |
| Sleep and activity | Five to six hours; ran twice this week |
| Safety | No suicidal thoughts since intake; safety plan on his phone |
| PHQ-9 | 14, down from 15 |
| System | Result | Finding |
|---|---|---|
| Breast | Positive | Tender breast tissue on both sides; no discharge or new lump |
| Genitourinary | Positive | Low libido and no morning erections; no testicular pain or swelling |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Positive | Low mood and interest, poor sleep; no suicidal thoughts, elevated mood, or racing thoughts |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1953-04-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1953-04-28 | Body height | 178 | cm | S |
| 1953-04-28 | Body weight | 71 | kg | S |
| 1953-04-28 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 1953-04-28 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1953-04-28 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1953-04-28 | Heart rate | 62 | /min | S |
| 1953-04-28 | Respiratory rate | 14 | /min | S |
| 1953-04-28 | Body temperature | 36.5 | Cel | S |
| 1953-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1953-04-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | {score} | S | ||
| 1953-04-28 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 46 | pg/mL | 7.6-42.6 pg/mL | High | S |
| 1953-04-28 | Lutropin [Units/volume] in Serum or Plasma | 0.9 | m[IU]/mL | 1.7-8.6 m[IU]/mL | Low | S |
Vital signs recorded on 1953-04-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tall, lean, tired |
| Breast | Examined with his agreement and a chaperone offered and declined: firm, tender, rubbery disc of glandular tissue about 4 cm across behind each nipple, centered and symmetric; no discrete or eccentric mass, skin change, nipple discharge, or axillary nodes |
| Genitourinary | Examined with his agreement: testes soft and slightly small, without masses, as the ultrasound confirmed |
| Mental status | Alert and cooperative; mood "still flat"; affect constricted but brightens on his work; thought process linear; no suicidal ideation; no psychotic features; insight and judgment good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment | active | confirmed | N62 | S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic. |
| Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue | active | confirmed | E23.1 | S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops. |
| Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment | active | confirmed | T38.5X5A | S — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm. |
| Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime) | active | confirmed | F32.1 | S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R). |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding of the bone-health workup. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Breast examination for size, tenderness, and any discrete mass | Every visit until the gynecomastia settles | Completed today | Firm, tender glandular tissue about 4 cm behind each nipple; symmetric; no discrete mass, skin change, discharge, or nodes |
| Imaging | Breast ultrasound or mammography | Only if the examination is equivocal or a discrete mass is felt | Not indicated | Typical bilateral, centered gynecomastia on examination |
| Imaging | Scrotal ultrasound | Once, in the gynecomastia workup | Completed today | Testes about 15 mL each, homogeneous; no mass; no varicocele |
| Laboratory | Estradiol and LH while the estrogen clears | Every 6 to 8 weeks after the exposure stops, until normal | Completed today | Estradiol 46 pg/mL, down from 148; LH 0.9 mIU/mL, still suppressed |
| Laboratory | hCG, AFP, liver, kidney, and thyroid tests | Once, at the initial workup | Up to date | All normal at intake two weeks ago |
| Medication safety | Testosterone therapy | Only for persistent, symptomatic, confirmed testosterone deficiency | Not indicated | Not given while the axis recovers: it would suppress LH and FSH again and is not indicated for a transient, drug-induced low testosterone |
| Referral | Endocrinology consultation | For gynecomastia with abnormal hormone results | Completed today | Seen today; drug-induced cause confirmed; recovery monitoring agreed |
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 14, down from 15 at intake |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since intake; PHQ-9 item 9 scored 0. Protective factors unchanged. Safety plan reviewed: on his phone, with 988 and the clinic number |
| Survey | Bipolar screen at the initial workup | Once, at the initial depression workup | Completed today | Interview found no past manic or hypomanic episode and no family history known to him; no Mood Disorder Questionnaire score is recorded |
| Self-management | Psychotherapy, sleep, running, and social contact | Every visit during active treatment | Completed today | Two sessions with a gay-affirming psychologist; sleep five to six hours; two runs alone |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Not on any of these drugs |
Goal progress:
Guideline basis: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Review in six weeks with hormone tests and PHQ-9. Next scheduled visit 1953-06-09: eight-week review of hormone recovery and depression treatment. [S]